New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
10:32 EDTIRWD, ACM, CECO, TCK, JAH, MNST, AVB, EDU, DARHigh option volume stocks
High option volume stocks: BXR IRWD ACM CECO TCK JAH MNST AVB EDU DAR
News For IRWD;ACM;CECO;TCK;JAH;MNST;AVB;EDU;DAR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
07:46 EDTJAHJarden anounces 3-for-2 stock split
Subscribe for More Information
07:23 EDTJAHJarden reports Q3 adjusted EPS $1.17, consensus $1.16
Subscribe for More Information
October 21, 2014
11:15 EDTACMHigh option volume stocks
High option volume stocks: DBA TUP CRI FCG TWC PLL ACM XRS RAI AMTD
October 20, 2014
08:08 EDTIRWDIronwood presents IW-9179 Phase IIa clinical study data
Subscribe for More Information
October 17, 2014
10:24 EDTACMAECOM Technology completes acquisition of URS Corporation
Subscribe for More Information
10:16 EDTCECOHigh option volume stocks
Subscribe for More Information
October 16, 2014
15:10 EDTIRWDAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
10:01 EDTTCKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:07 EDTACMAECOM, URS announce preliminary merger consideration
Subscribe for More Information
08:02 EDTIRWDIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
05:34 EDTTCKTeck Resources initiated with an Equal Weight at Barclays
Subscribe for More Information
October 15, 2014
10:02 EDTEDUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTMNSTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:50 EDTACMAECOM Technology to host special shareholder meeting
Subscribe for More Information
08:34 EDTEDUNew Oriental Education downgraded to Sell from Neutral at Goldman
Subscribe for More Information
08:28 EDTMNSTMonster Beverage upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
07:07 EDTCECOFor profit education positive catalysts outweigh negative, says Wells Fargo
Wells Fargo expects for-profit education stocks to benefit from improved hiring trends and a sale by Corinthian of its assets that, according t othe firm ,would set a valuation floor for the sector. The firm continues to believe that the final gainful employment rule will be neutral to positive for the group. Wells favors the option value on the long side for the sector. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
October 13, 2014
17:24 EDTACMS&P announces changes to the S&P MidCap 400 and S&P SmallCap 600 indices
Subscribe for More Information
10:26 EDTEDUHigh option volume stocks
Subscribe for More Information
07:26 EDTMNSTAB InBev has studied potential deal to acquire PepsiCo, Bloomberg says
Anheuser-Busch InBev (BUD), which has a history of growth via acquisition and has been speculated to be targeting peer SABMiller (SBMRY), has also studied whether a merger with PepsiCo (PEP) makes sense, according to Bloomberg, citing people familiar with the matter. The report added that one source said no talks between Anheuser-Busch and Pepsi are ongoing, no deal is imminent, and the scenario is among many that has been examined. The report also noted that Albert Fried views Monster Beverage (MNST) and Keurig Green Mountain (GMCR) as other suitable targets for AB InBev. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use